Navigating Challenging Conversations About Nonmedical Opioid Use in the Context of Oncology.
Cancer pain
Opioid use disorder
Opioids
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
08
04
2019
accepted:
08
05
2019
pubmed:
4
6
2019
medline:
7
8
2020
entrez:
2
6
2019
Statut:
ppublish
Résumé
Opioids are commonly used in the context of oncology to treat cancer-related pain. In the context of increased awareness of nonmedical use of opioids, including misuse and opioid use disorder among individuals with cancer, oncologists may find themselves having difficult conversations with patients regarding the use of opioids. We offer a review of pertinent literature and a conversation framework for providers to use, as well as key communication strategies for clinicians. Building on the therapeutic alliance between provider and patient, emphasizing the importance of nonabandonment, and using a benefit-to-harm framework, we hope clinicians find they are more able to navigate these challenging but important conversations with patients. IMPLICATIONS FOR PRACTICE: Providers may find it difficult and uncomfortable to discuss nonmedical use of opioids with patients. To the authors' knowledge, no previous articles discuss ways to communicate about nonmedical use of opioids in the oncology setting. This work borrows from other specialties and offers a communication framework and key communication strategies to help clinications communicate more effectively with patients who may have an opioid use disorder or may be using their prescribed opioids for reasons other than their pain.
Identifiants
pubmed: 31152081
pii: theoncologist.2019-0277
doi: 10.1634/theoncologist.2019-0277
pmc: PMC6795161
doi:
Substances chimiques
Analgesics, Opioid
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1299-1304Informations de copyright
© AlphaMed Press 2019.
Déclaration de conflit d'intérêts
Disclosures of potential conflicts of interest may be found at the end of this article.
Références
J Gen Intern Med. 2009 Apr;24(4):482-8
pubmed: 19189194
Cochrane Database Syst Rev. 2017 Jul 06;7:CD012592
pubmed: 28683172
Patient Educ Couns. 2004 Mar;52(3):297-305
pubmed: 14998600
Cancer. 2009 Jul 15;115(14):3302-11
pubmed: 19484795
Arch Intern Med. 2009 Mar 9;169(5):474-9
pubmed: 19273777
Am J Public Health. 2018 Oct;108(10):1394-1400
pubmed: 30138057
Ann Intern Med. 2017 Aug 1;167(3):181-191
pubmed: 28715848
Ann Intern Med. 1995 Mar 1;122(5):368-74
pubmed: 7847649
JAMA. 1997 Aug 13;278(6):502-9
pubmed: 9256226
Pain Med. 2011 Jun;12(6):890-7
pubmed: 21539703
Pain Med. 2013 Nov;14(11):1689-97
pubmed: 23870100
Eur J Pain. 2016 May;20(5):675-88
pubmed: 26492629
Pain Med. 2018 Nov 1;19(11):2154-2165
pubmed: 29401356
J Gen Intern Med. 2008 Sep;23(9):1336-8
pubmed: 18516649
Cancer. 2015 Oct 1;121(19):3534-42
pubmed: 26042653
Psychiatr Serv. 2013 Mar 1;64(3):264-9
pubmed: 23573532
Oncologist. 2018 Feb;23(2):263-270
pubmed: 29021378
N Engl J Med. 2016 Jan 14;374(2):154-63
pubmed: 26760086
Pain. 2014 Dec;155(12):2575-82
pubmed: 25261714
Patient Educ Couns. 2013 Nov;93(2):197-202
pubmed: 23916677
J Pain Symptom Manage. 2019 Jan;57(1):20-27
pubmed: 30342243
Drug Alcohol Rev. 2005 Mar;24(2):143-55
pubmed: 16076584
J Pain Symptom Manage. 2012 Feb;43(2):253-60
pubmed: 21680141
Br J Pain. 2012 Feb;6(1):36-42
pubmed: 26516464
Pain Med. 2010 Dec;11(12):1791-8
pubmed: 21029353
Am J Public Health. 2013 Apr;103(4):e1-2
pubmed: 23409913
J Pain Symptom Manage. 2000 Mar;19(3):229-34
pubmed: 10760628
Oncologist. 2015 Jun;20(6):692-7
pubmed: 25933929
Science. 1997 Oct 3;278(5335):45-7
pubmed: 9311924
J Gen Intern Med. 2002 May;17(5):327-33
pubmed: 12047728